DNA direct reversal repair and alkylating agent drug resistance

Abstract

DNA direct reversal repair (DRR) is unique in that no DNA synthesis is required to correct the error and therefore repair via such mechanisms are error-free. In humans, DRR is carried out by two different pathways: the O6-methylguanine-DNA methyltransferase (MGMT) and the alkylated DNA repair protein B (AlkB) homologs. The use of alkylating agents is the standard of care for many cancers. However, the use of those drugs is usually halted when resistance develops. This review will examine repair of alkylating agent damage mediated by DRR, resistance mechanisms and potential ways to overcome such resistance.

Keywords

Direct reversal repair / O6-methylguanine-DNA methyltransferase / AlkB homologs / resistance to alkylating agents

References

[1] Fu D,Samson LD.Balancing repair and tolerance of DNA damage caused by alkylating agents..Nat Rev Cancer2012;12:104-20 PMCID:PMC3586545

[2] Ahmad A,O’Connor TR.Clark Chen.Direct Reversal Repair in Mammalian Cells..Advances in DNA Repair.2015;Rijeka, CroatiaInTech95-128

[3] Kondo N,Ono K.DNA damage induced by alkylating agents and repair pathways..J Nucleic Acids2010;2010:543531 PMCID:PMC2989456

[4] Tano K,Collier J,Mitra S.Isolation and structural characterization of a cDNA clone encoding the human DNA repair protein for O6-alkylguanine..Proc Natl Acad Sci U S A1990;87:686-90 PMCID:PMC53330

[5] Hayakawa H,Sekiguchi M.Expression and cloning of complementary DNA for a human enzyme that repairs O6-methylguanine in DNA..J Mol Biol1990;213:739-47

[6] Xu-Welliver M.Degradation of the alkylated form of the DNA repair protein, O(6)-alkylguanine-DNA alkyltransferase..Carcinogenesis2002;23:823-30

[7] Lindahl T,Robins P.Suicide inactivation of the E. coli O6-methylguanine-DNA methyltransferase..EMBO J1982;1:1359-63 PMCID:PMC553217

[8] Warren JJ,Beese LS.The structural basis for the mutagenicity of O(6)-methyl-guanine lesions..Proc Natl Acad Sci U S A2006;103:19701-6 PMCID:PMC1750904

[9] Costello JF,Kroes RA.Methylation-related chromatin structure is associated with exclusion of transcription factors from and suppressed expression of the O-6-methylguanine DNA methyltransferase gene in human glioma cell lines..Mol Cell Biol1994;14:6515-21 PMCID:PMC359181

[10] Costello JF,Tano K,Pieper RO.Graded methylation in the promoter and body of the O6-methylguanine DNA methyltransferase (MGMT) gene correlates with MGMT expression in human glioma cells..J Biol Chem1994;269:17228-37

[11] Harris LC,Brent TP.In vitro methylation of the human O6-methylguanine-DNA methyltransferase promoter reduces transcription..Biochim Biophys Acta1994;1217:141-6

[12] Esteller M,Sanchez-Cespedes M.Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis..Cancer Res2000;60:2368-71

[13] Qi Z.Association between MGMT status and response to alkylating agents in patients with neuroendocrine neoplasms: a systematic review and meta-analysis..Biosci Rep2020;40:BSR20194127 PMCID:PMC7098124

[14] Mitra S.Regulation of repair of alkylation damage in mammalian genomes..Prog Nucleic Acid Res Mol Biol1993;44:109-42

[15] Christmann M,Roos WP.O(6)-Methylguanine-DNA methyltransferase (MGMT) in normal tissues and tumors: enzyme activity, promoter methylation and immunohistochemistry..Biochim Biophys Acta2011;1816:179-90

[16] Hegi ME,Gorlia T.MGMT gene silencing and benefit from temozolomide in glioblastoma..N Engl J Med2005;352:997-1003

[17] Kulke MH,Frauenhoffer C.O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors..Clin Cancer Res2009;15:338-45 PMCID:PMC3100724

[18] Boeckmann L,Kuschal C.Temozolomide chemoresistance heterogeneity in melanoma with different treatment regimens: DNA damage accumulation contribution..Melanoma Res2011;21:206-16

[19] Cen L,Pokorny JL.Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models..Neuro Oncol2013;15:735-46 PMCID:PMC3661094

[20] Fan CH,Cao H,Chen L.O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas..Cell Death Dis2013;4:e876 PMCID:PMC4648381

[21] Bengtsson D,Andersen M.Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide..J Clin Endocrinol Metab2015;100:1689-98

[22] Esteller M,Andion E.Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents..N Engl J Med2000;343:1350-4

[23] Middlemas DS,Kirstein MN.Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models..Clin Cancer Res2000;6:998-1007

[24] Bruheim S,Breistol K,Fodstad O.Human osteosarcoma xenografts and their sensitivity to chemotherapy..Pathol Oncol Res2004;10:133-41

[25] Pećina-Šlaus N,Salamon I.Mismatch repair pathway, genome stability and cancer..Front Mol Biosci2020;7:122 PMCID:PMC7332687

[26] Fishel R,Rao MR.The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer..Cell1993;75:1027-38

[27] Leach FS,Papadopoulos N.Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer..Cell1993;75:1215-25

[28] Young J,Gustafson C.Genomic instability occurs in colorectal carcinomas but not in adenomas..Hum Mutat1993;2:351-4

[29] Felsberg J,Eigenbrod S.Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas..Int J Cancer2011;129:659-70

[30] von Bueren AO,Hagel C.Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours..Br J Cancer2012;107:1399-408 PMCID:PMC3494444

[31] Shinsato Y,Yunoue S.Reduction of MLH1 and PMS2 confers temozolomide resistance and is associated with recurrence of glioblastoma..Oncotarget2013;4:2261-70 PMCID:PMC3926825

[32] Taverna P,Hanson AJ,Gerson SL.Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen..Cancer Chemother Pharmacol2000;46:507-16

[33] Helleman J,Dinjens WN.Mismatch repair and treatment resistance in ovarian cancer..BMC Cancer2006;6:201 PMCID:PMC1557864

[34] Gee ME,McCormick A.DNA damage repair in ovarian cancer: unlocking the heterogeneity..J Ovarian Res2018;11:50 PMCID:PMC6011341

[35] Karran P.Self-destruction and tolerance in resistance of mammalian cells to alkylation damage..Nucleic Acids Res1992;20:2933-40 PMCID:PMC312419

[36] Day RS3rd,Yarosh DB.The role of O6-methylguanine in human cell killing, sister chromatid exchange induction and mutagenesis: a review..J Cell Sci Suppl1987;6:333-53

[37] de Wind N,Berns A,te Riele H.Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer..Cell1995;82:321-30

[38] Kawate H,Tsuzuki T.Separation of killing and tumorigenic effects of an alkylating agent in mice defective in two of the DNA repair genes..Proc Natl Acad Sci U S A1998;95:5116-20 PMCID:PMC20223

[39] Takagi Y,Sanada M,Yamaizumi M.Roles of MGMT and MLH1 proteins in alkylation-induced apoptosis and mutagenesis..DNA Repair (Amst)2003;2:1135-46

[40] Duncan T,Koivisto P,Lindahl T.Reversal of DNA alkylation damage by two human dioxygenases..Proc Natl Acad Sci U S A2002;99:16660-5 PMCID:PMC139200

[41] Koivisto P,Lindahl T.Demethylation of 3-methylthymine in DNA by bacterial and human DNA dioxygenases..J Biol Chem2004;279:40470-4

[42] Aas PA,Falnes PO.Human and bacterial oxidative demethylases repair alkylation damage in both RNA and DNA..Nature2003;421:859-63

[43] Shen L,He C.Mechanism and function of oxidative reversal of DNA and RNA methylation..Annu Rev Biochem2014;83:585-614 PMCID:PMC4786441

[44] Ciesielski P,Krześlak A.TET proteins and epigenetic modifications in cancers..Postepy Hig Med Dosw (Online)2015;69:1371-83

[45] Fedeles BI,Delaney JC,Essigmann JM.The AlkB Family of Fe(II)/alpha-Ketoglutarate-dependent Dioxygenases: Repairing Nucleic Acid Alkylation Damage and Beyond..J Biol Chem2015;290:20734-42 PMCID:PMC4543635

[46] Guengerich FP.Introduction: Metals in Biology: alpha-Ketoglutarate/Iron-Dependent Dioxygenases..J Biol Chem2015;290:20700-1 PMCID:PMC4543631

[47] Hashimoto H,Vertino PM.The Mechanisms of Generation, Recognition, and Erasure of DNA 5-Methylcytosine and Thymine Oxidations..J Biol Chem2015;290:20723-33 PMCID:PMC4543634

[48] Nay SL,Bates SE.Alkbh2 protects against lethality and mutation in primary mouse embryonic fibroblasts..DNA Repair (Amst)2012;11:502-10 PMCID:PMC3614354

[49] Furrer A.Handling the 3-methylcytosine lesion by six human DNA polymerases members of the B-, X- and Y-families..Nucleic Acids Res2014;42:553-66 PMCID:PMC3874200

[50] Lee DH,Cai S,Pfeifer GP.Repair of methylation damage in DNA and RNA by mammalian AlkB homologues..J Biol Chem2005;280:39448-59

[51] Pilžys T,Kukwa W.ALKBH overexpression in head and neck cancer: potential target for novel anticancer therapy..Sci Rep2019;9:13249 PMCID:PMC6744417

[52] Yamato I,Shimada K.PCA-1/ALKBH3 contributes to pancreatic cancer by supporting apoptotic resistance and angiogenesis..Cancer Res2012;72:4829-39

[53] Stefansson OA,van der Horst J.CpG promoter methylation of the ALKBH3 alkylation repair gene in breast cancer..BMC Cancer2017;17:469 PMCID:PMC5498885

[54] Johannessen TC,Grudic A,Tysnes BB.The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cells..Neuro Oncol2013;15:269-78 PMCID:PMC3578482

[55] Konishi N,Ishida E.High expression of a new marker PCA-1 in human prostate carcinoma..Clin Cancer Res2005;11:5090-7

[56] Liu BQ,Li PH,Zhang T.Prostate cancer antigen-1 as a potential novel marker for prostate cancer..Asian J Androl2007;9:821-6

[57] Wang P,Zhang C.Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas..Oncogene2013;32:3091-100 PMCID:PMC3500578

[58] Yang H,Guan KL.IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives..Clin Cancer Res2012;18:5562-71 PMCID:PMC3897211

[59] Schaap FG,Bovée JV.Mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 in tumors..Adv Anat Pathol2013;20:32-8

[60] Wang P,Ma S.Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents..Cell Rep2015;13:2353-61 PMCID:PMC4694633

[61] Tran TQ,Lowman XH.Glutamine deficiency induces DNA alkylation damage and sensitizes cancer cells to alkylating agents through inhibition of ALKBH enzymes..PLoS Biol2017;15:e2002810 PMCID:PMC5673162

[62] Voigt JM.O6-methylguanine-induced replication blocks..Carcinogenesis1995;16:1775-82